HomeCompareRAONF vs ORCC

RAONF vs ORCC: Dividend Comparison 2026

RAONF yields 76.92% · ORCC yields 9.79%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RAONF wins by $1.42M in total portfolio value
10 years
RAONF
RAONF
● Live price
76.92%
Share price
$2.60
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.45M
Annual income
$406,212.55
Full RAONF calculator →
ORCC
ORCC
● Live price
9.79%
Share price
$13.48
Annual div
$1.32
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$1.04
Full ORCC calculator →

Portfolio growth — RAONF vs ORCC

📍 RAONF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRAONFORCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RAONF + ORCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RAONF pays
ORCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RAONF
Annual income on $10K today (after 15% tax)
$6,538.46/yr
After 10yr DRIP, annual income (after tax)
$345,280.67/yr
ORCC
Annual income on $10K today (after 15% tax)
$832.34/yr
After 10yr DRIP, annual income (after tax)
$0.88/yr
At 15% tax rate, RAONF beats the other by $345,279.78/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RAONF + ORCC for your $10,000?

RAONF: 50%ORCC: 50%
100% ORCC50/50100% RAONF
Portfolio after 10yr
$733.2K
Annual income
$203,106.79/yr
Blended yield
27.70%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ORCC right now

RAONF
No analyst data
Altman Z
259.5
Piotroski
2/9
ORCC
Analyst Ratings
9
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$16.00
+18.7% upside vs current
Range: $16.00 — $16.00
Altman Z
0.5
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RAONF buys
0
ORCC buys
0
No recent congressional trades found for RAONF or ORCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRAONFORCC
Forward yield76.92%9.79%
Annual dividend / share$2.00$1.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$1.45M$21.4K
Annual income after 10y$406,212.55$1.04
Total dividends collected$1.25M$1.0K
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: RAONF vs ORCC ($10,000, DRIP)

YearRAONF PortfolioRAONF Income/yrORCC PortfolioORCC Income/yrGap
1← crossover$18,392$7,692.31$11,190$489.61+$7.2KRAONF
2$32,902$13,222.36$12,229$256.01+$20.7KRAONF
3$57,311$22,106.15$13,216$130.74+$44.1KRAONF
4$97,310$35,987.08$14,207$66.02+$83.1KRAONF
5$161,228$57,105.82$15,234$33.17+$146.0KRAONF
6$260,939$88,425.56$16,317$16.62+$244.6KRAONF
7$412,955$133,749.94$17,468$8.32+$395.5KRAONF
8$639,683$197,821.28$18,695$4.16+$621.0KRAONF
9$970,847$286,385.73$20,006$2.08+$950.8KRAONF
10$1,445,019$406,212.55$21,407$1.04+$1.42MRAONF

RAONF vs ORCC: Complete Analysis 2026

RAONFStock

Race Oncology Limited operates as a precision oncology company in Australia. The company is developing Zantrene, a potent small molecule inhibitor of the fatso/fat mass and obesity associated protein to treat for melanoma and clear cell renal cell carcinoma, as well as acute myeloid leukaemia, breast, and ovarian cancers, which is in Phase II/III clinical trial. It has a preclinical research program with the University of Newcastle for investigating Zantrene; and strategic collaboration with the University of Wollongong to evaluate Zantrene formulations. The company was formerly known as Coronado Resources Limited and changed its name to Race Oncology Limited in July 2016. Race Oncology Limited was incorporated in 2011 and is based in Sydney, Australia.

Full RAONF Calculator →

ORCCBDC

Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.

Full ORCC Calculator →
📬

Get this RAONF vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RAONF vs SCHDRAONF vs JEPIRAONF vs ORAONF vs KORAONF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.